About MultiVir

MultiVir is a clinical stage, immune oncology company pioneering a new fields of cancer therapeutics termed “Tumor Suppressor Immune Gene Therapy” and “Dendritic Cell Therapeutic Vaccines” employing multiple viral delivery platforms. MultiVir’s oncology experimental products deliver tumor suppressor and immunotherapeutic genes. The company’s broad technology platforms target cancers’ most fundamental and common molecular defects.

MultiVir’s product candidates have unique therapeutic activities with multiple mechanisms of action. MultiVir’s tumor suppressor gene therapies have the ability to inhibit tumor growth, kill cancerous cells, enhance anti-tumor immunity, decrease tumor blood supply, and the potential to sensitize tumors to conventional immunotherapy, chemotherapy and radiation treatments. MultiVir’s Ad-p53 Dendritic Cell Therapeutic Vaccine (Ad.p53-DC) is an investigational immuno-stimulatory therapy designed to activate the immune system to attack tumor cells.